Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAT-Trial: Eptinezumab for Painful Diabetic Neuropathy
NCT05937152Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jan 2025
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing Eptinezumab Group with Placebo Group (2 arms). Primary endpoint: Change in pain intensity at 24 weeks. Planned start Jan 2025; status: withdrawn.
02
Drugs
eptinezumab
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT05937152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937152.